FDAsafety guidance83% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Bristol-Myers Squibb.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Ovarian Cancer
- Sub-indication
- General
Related signal: Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis